Recombinant polypeptide construct comprising Plasmodium falciparum circumsporozoite protein HLA class I restricted T-cell epitopes

Patent metadata

Field	Value
Publication number	US-9645147-B2
Application number	US-201314069656-A
Country	US
Kind code	B2
Filing date	Nov 1, 2013
Priority date	Nov 9, 2012
Publication date	May 9, 2017
Grant date	May 9, 2017

Abstract

The invention relates to a recombinant polypeptide construct comprising epitopes from Plasmodium falciparum protein circumsporozoite protein (CSP). The epitopes contain HLA class I binding motifs and stimulate an anti-malaria CD8 + T-cell response. The polypeptides can be incorporated into immunogenic formulations against malaria. Additionally, the antigens are useful for facilitating evaluation of immunogenicity of candidate malaria vaccines.

First claim

What is claimed is:

1. A recombinant polypeptide construct comprising the amino acid sequences SEQ ID No. 5, 6 and 7, and one or more amino acid sequences selected from the group consisting of SEQ ID No. 1, 2, 3, 4, 8, 9, 10, and 11, wherein each of the amino acid sequences of SEQ ID No. 5, 6, 7 and on or more amino acid sequences selected from the group consisting of SEQ ID No. 1, 2, 3, 4, 8, 9, 10 and 11 contain a T-cell epitope isolated from Plasmodium falciparum circumsporozoite protein and, wherein said amino acid sequences are linked to each other directly or linked to each other via polypeptide spacer sequences, wherein said spacer sequences do not contain a T-cell epitope, and wherein the polypeptide construct is expressed from a DNA or viral expression system.

2. The recombinant polypeptide construct of claim 1 , wherein the spacer sequences are amino acid sequences of 1 to 10 amino acids in length.

3. A method of inducing an immune response in a mammal against Plasmodium falciparum comprising administering one or more doses of the composition of claim 1 .

4. A method of inducing an immune response in a mammal against Plasmodium falciparum comprising administering the composition of claim 1 as one or more priming immunizations or one or more boosting immunizations, or both.

5. The method of claim 3 , wherein said recombinant polypeptide construct is expressed from a DNA or viral expression vector.

6. The method of claim 3 , wherein one or more priming or one or more boosting immunizations comprises irradiated sporozoites.

7. The method of claim 5 , wherein said DNA or viral expression vector is selected from the group consisting of DNA plasmid, alphavirus replicon, adenovirus, poxvirus, adeno-associated virus, cytomegalovirus, canine distemper virus, yellow fever virus and retrovirus.

8. The method of claim 7 , wherein said priming immunization vector is an alphavirus vector and said boosting immunization is a non-alphavirus vector.

9. The method of claim 7 , wherein said priming immunization comprises an expression vector that is a DNA plasmid or an adenovirus and the boosting immunization comprises an expression vector selected from the group consisting of adenovirus, adenovirus heterologous to the priming adenovirus, poxvirus and a recombinant polypeptide construct comprising the amino acid sequences SEQ ID No. 5, 6 and 7, and one or more amino acid sequences selected from the group consisting of SEQ ID No. 1, 2, 3, 4, 8, 9, 10, and 11, wherein each of the amino acid sequences of SEQ ID No. 5, 6, 7 and on or more amino acid sequences selected from the group consisting of SEQ ID No. 1, 2, 3, 4, 8, 9, 10 and 11 contain a T-cell epitope isolated from Plasmodium falciparum circumsporozoite protein and, wherein said amino acid sequences are linked to each other directly or linked to each other via polypeptide spacer sequences, wherein said spacer sequences do not contain a T-cell epitope, and wherein the polypeptide construct is expressed from a DNA or viral expression system.

10. The method of claim 8 , wherein said alphavirus vector is a preparation is selected from the group consisting of RNA replicon, DNA replicon and alphavirus replicon particles.

11. The method of claim 8 , wherein said non-alphavirus expression system is selected from the group consisting of poxvirus, adenovirus, adeno-associated virus and retrovirus.

12. The method of claim 10 , wherein the alphavirus is selected from the group consisting of Venezuelan Equine Encephalitis Virus, Semliki Forest Virus and Sindbis Virus.

13. The method of claim 11 , wherein the poxvirus is selected from the group consisting of cowpox, canarypox, vaccinia, modified vaccinia Ankara, or fowlpox.

Assignees

• Sedegah Martha
• Richie Thomas
• Us Navy

Inventors

• Sedegah Martha
• Richie Thomas

Classifications

• A61K39/015

  Hemosporidia antigens, e.g. Plasmodium antigens · CPC title

• G01N2333/445

  Plasmodium · CPC title

• C07K14/445

  Plasmodium · CPC title

• G01N33/56905 Primary

  Protozoa · CPC title

• G01N33/505

  involving T-cells · CPC title